A landmark study titled “COVID-19 Vaccine Linked to Longer Survival in Cancer Patients” has revealed that people with advanced lung or skin cancer who received an mRNA COVID-19 vaccine within 100 days of starting immunotherapy lived significantly longer than those who did not. Conducted by researchers from the University of Florida (UF) and the University of Texas MD Anderson Cancer Center, the findings were presented at the 2025 European Society for Medical Oncology Congress in Berlin and mark a major step in exploring how mRNA technology could strengthen cancer treatment.A Milestone in mRNA ResearchThis study represents the culmination of more than a decade of UF research on mRNA-based cancer therapies. Lead investigator Dr Elias Sayour, a pediatric oncologist at UF Health, called the findings “extraordinary,” noting that the vaccine’s immune-boosting effect could help design a universal, off-the-shelf cancer vaccine capable of enhancing immunotherapy responses.mRNA, or messenger RNA, is a molecule that carries genetic instructions to make proteins. It forms the basis of COVID vaccines developed during the pandemic, and scientists now believe this same mechanism could be harnessed to amplify the body’s cancer-fighting abilities.How the Study Was ConductedResearchers analyzed medical records of over 1,000 patients with stage III and IV non-small-cell lung cancer or metastatic melanoma treated at MD Anderson between 2019 and 2023. Of these, 180 lung-cancer patients and 43 melanoma patients received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy. Their outcomes were compared with 704 and 167 unvaccinated patients, respectively.The results were striking. Vaccinated lung-cancer patients showed a median survival of 37.3 months, nearly double the 20.6 months observed in unvaccinated counterparts. Among melanoma patients, survival rose from 26.7 months to about 30–40 months, with several patients still alive at data cut-off — suggesting an even greater long-term benefit.Importantly, the effect was specific to mRNA COVID vaccines; flu and pneumonia shots did not produce similar outcomes.The Science Behind the BoostEarlier this year, Dr Sayour’s lab discovered that to trigger a strong immune attack, targeting a single tumor protein wasn’t necessary. Instead, stimulating the immune system as if fighting a viral infection worked better. When this nonspecific mRNA vaccine was combined with immune checkpoint inhibitors — drugs that “release the brakes” on immune cells — mice showed powerful antitumor responses.Building on this, the team theorized that the COVID mRNA vaccine might act like an immune flare, mobilizing immune cells from tumor zones to lymph nodes where cancer defense is stronger. This mechanism, Sayour explained, could make previously unresponsive cancers respond to treatment.Implications and Next StepsAlthough this is an observational study and cannot yet prove causality, experts are optimistic. UF’s Dr Duane Mitchell emphasized that while more trials are needed, such a large survival benefit “is the type of treatment effect we rarely see.”A large-scale clinical trial through the UF-led OneFlorida+ Research Network is now planned to verify these findings across hospitals in several U.S. states.If confirmed, the discovery could reshape how cancer is treated — turning vaccines from preventive tools into active partners in therapy. For patients battling advanced cancers, this could mean something profoundly valuable: more time and renewed hope.
Email
Google
Facebook Email Google Facebook